Anti-Mullerian Hormone levels after laparoscopic treatment in women with anovulatory polycystic ovary syndrome
Phase 2
Completed
- Conditions
- Polycystic ovary syndrome.Sclerocystic ovary syndrome
- Registration Number
- IRCT2015020420374N2
- Lead Sponsor
- Vise chanceller for research, Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Patients with polycystic ovary syndrome; PCOS patients resistance to drug clomiphene citrate; patients with symptoms of amenorrhea. Exclusion criteria: Patients with symptoms of oligomenorrhea; patients who were outside the age range.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum anti-mullerian levels. Timepoint: Pre-treatment and 1 week, 1 and 3 month after treatment. Method of measurement: Serum anti-mullerian hormon levels on nanomoles per mml.
- Secondary Outcome Measures
Name Time Method Ovarian response to treatment method. Timepoint: 1 and 3 month. Method of measurement: The first menstural cycle after treatment.